Brief Article
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Mar 14, 2011; 17(10): 1304-1307
Published online Mar 14, 2011. doi: 10.3748/wjg.v17.i10.1304
Does deep sedation impact the results of 48 hours catheterless pH testing?
Vineet Korrapati, Jay P Babich, Anil Balani, James H Grendell, Kavita R Kongara
Vineet Korrapati, Jay P Babich, James H Grendell, Kavita R Kongara, Department of Gastroenterology and Hepatology, Winthrop University Hospital, Mineola, NY 11501, United States
Anil Balani, Department of Gastroenterology and Hepatology, UMDNJ-RWJ Medical School, New Brunswick, NJ 08901, United States
Author contributions: Korrapati V and Balani A performed the majority of the data collection and analysis; Kongara KR performed the Bravo placement; Korrapati V and Babich JP wrote the manuscript; Kongara KR and Grendell JH were involved in editing the manuscript.
Supported by Winthrop University Hospital
Correspondence to: Dr. Vineet Korrapati, MD, Department of Gastroenterology and Hepatology, Winthrop University Hospital, 222 Station Plaza-Suite 428, Mineola, NY 11501, United States. vkorrapati@winthrop.org
Telephone: +1-516-6632066 Fax: +1-516-6634655
Received: April 20, 2010
Revised: September 27, 2010
Accepted: October 4, 2010
Published online: March 14, 2011
Abstract

AIM: To study a cohort of patients undergoing 48 h Bravo pH testing receiving deep sedation with propofol.

METHODS: We retrospectively reviewed the charts of 197 patients (81 male, 116 female) who underwent Bravo esophageal pH monitoring from July 2003 to January 2008. All patients underwent Bravo pH probe placement via esophagogastroduodenoscopy (EGD) and received propofol for sedation. Patients on a proton pump inhibitor (89 patients) were excluded. Acid reflux variables measured included the total, upright, and supine fractions of time at pH < 4 and DeMeester score, and were compared between day 1 and day 2.

RESULTS: Of the 108 patients that were included in the study, the most common indication for Bravo pH monitoring was heartburn, with chest pain being the second most common. A signed rank test revealed no statistically significant difference between day 1 and day 2 reflux episodes.

CONCLUSION: Patients who received propofol for sedation for EGD with Bravo pH capsule placement did not experience any significant difference in reflux episodes from day 1 to day 2.

Keywords: Esophagus, Bravo study, Propofol, pH capsule, Gastroesophageal reflux disease